Detail akcie Uniqure online

Business Summary: Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Uniqure NV revenues increased from $1.6M to $3.6M. Net loss increased 23% to $53.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Foreign currency (losses) / gains, net decrease from $7.2M (income) to $2.3M (expense), Labor & Related Expenses in SGA increase of 80% to $9.9M (expense), Selling.